The start of a new year is an ideal time to reflect and make plans for the year. This year marks a great start for Samsung Bioepis, with the opening of our new headquarters in Korea’s ‘Bio Cluster’ of Songdo.
We started as a R&D center in 2012, and since then we have been tirelessly expanding our biosimilar portfolios and developing our process innovation so as to sharpen our competitiveness and become a leader in the global biopharmaceutical industry.
Having our new headquarters is part of our efforts to accelerate our innovation and to propel our future growth. Our new headquarters is equipped with the state-of-the art laboratories, which will serve as the hub of Samsung Bioepis’ drive for development of next-generation biologic medicines.
Science and technology give us the confidence in our ability to drive new innovation, to develop next-generation of biologic medicine and to deliver our high-quality biologic medicines with agility and with quality assurance. Technology is the key to increase access to scientifically-proven medicines for patients around the world and unlock the potential of biosimilars.
Looking back on Samsung Bioepis’ path for the past nine years, we have rapidly grown to have five biologic products in immunology and oncology with more than 215,000 patients treated with the company’s immunology products in Europe alone. We keep on improving access to medicines through our own process innovation development platform and currently have five biologic candidates in our pipeline ranging from hematology and ophthalmology.
In 2020, Samsung Bioepis had been through an unprecedented year like many other businesses in the face of the unexpected global impact of COVID-19. But at the same time, it was a busy and remarkable year with the launch of oncology biosimilar each in the United States and Europe, and the acceptance of a proposed biosimilar to ranibizumab for review by the U.S. Food and Drug Administration and the European Medicines Agency.
Looking forward to 2021 and beyond, Samsung Bioepis believes COVID-19 not only presents a set of challenges but also opportunities for us to redefine and reimagine the global biopharmaceutical industry.
Demand for affordable and reliable treatments will be here to stay with stronger interests in having a healthy life, sparked by COVID-19. Building on our expertise and experience, we will continue to produce high-quality treatments to meet patients’ needs and enhance their access to medicines.
With the start of a new year and the opening of our new headquarters, we are more than ready to push ourselves to the next level of growth and innovation.